Get key Q3 2025 earnings call insights on Cytosorbents (CTSO): growth drivers, FDA progress, cost controls, and outlook.
11h
Xos Extends Profitability Streak with Strong Q3 2025 Performance and Positive Operating Cash Flow
Delivered 130 units and generated $16.5 million in revenueAchieved 15.3% Gross Margin and a second consecutive quarter of positive free cash flow ...
LandBridge is emerging as a royalty landlord in the heart of the Permian water bottleneck, with a fee-based model that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback